GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » ROA %

Theriva Biologics (Theriva Biologics) ROA % : -39.75% (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Theriva Biologics's annualized Net Income for the quarter that ended in Mar. 2024 was $-20.66 Mil. Theriva Biologics's average Total Assets over the quarter that ended in Mar. 2024 was $51.97 Mil. Therefore, Theriva Biologics's annualized ROA % for the quarter that ended in Mar. 2024 was -39.75%.

The historical rank and industry rank for Theriva Biologics's ROA % or its related term are showing as below:

TOVX' s ROA % Range Over the Past 10 Years
Min: -174.99   Med: -69.01   Max: -27.68
Current: -31.85

During the past 13 years, Theriva Biologics's highest ROA % was -27.68%. The lowest was -174.99%. And the median was -69.01%.

TOVX's ROA % is ranked better than
56.85% of 1555 companies
in the Biotechnology industry
Industry Median: -35.15 vs TOVX: -31.85

Theriva Biologics ROA % Historical Data

The historical data trend for Theriva Biologics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics ROA % Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -64.60 -78.32 -36.22 -27.68 -28.88

Theriva Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.63 -30.50 -20.81 -37.58 -39.75

Competitive Comparison of Theriva Biologics's ROA %

For the Biotechnology subindustry, Theriva Biologics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's ROA % distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's ROA % falls into.



Theriva Biologics ROA % Calculation

Theriva Biologics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-18.349/( (71.861+55.219)/ 2 )
=-18.349/63.54
=-28.88 %

Theriva Biologics's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-20.66/( (55.219+48.73)/ 2 )
=-20.66/51.9745
=-39.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


Theriva Biologics  (AMEX:TOVX) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-20.66/51.9745
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-20.66 / 0)*(0 / 51.9745)
=Net Margin %*Asset Turnover
=N/A %*0
=-39.75 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Theriva Biologics ROA % Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (Theriva Biologics) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Executives
Steven A Shallcross director, officer: CEO and CFO C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro officer: Chief Operating Officer 9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan director
Scott Tarriff director 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman officer: CHIEF MEDICAL OFFICER 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley director C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp 10 percent owner 20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne officer: CHIEF FINANCIAL OFFICER 27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks director C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr director, officer: CEO & President C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome officer: Chief Scientific Officer 3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman director
Wayne George Holman 10 percent owner 430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022

Theriva Biologics (Theriva Biologics) Headlines

From GuruFocus